Summary & Overview
CPT 0008U: H. pylori Antibiotic Resistance Panel, Gene Sequence Analysis
CPT code 0008U designates a Proprietary Laboratory Analyses (PLA) test: the AmHPR Helicobacter pylori Antibiotic Resistance Panel by American Molecular Laboratories, Inc. This sequencing-based molecular assay evaluates fresh tissue or fecal specimens to identify H. pylori resistance to antibiotics, informing antimicrobial management and public health surveillance. As a PLA code, 0008U maps to one manufacturer-specific test and is important for laboratory billing clarity and payer coverage determinations nationwide.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns, coding and billing considerations for PLA-coded molecular diagnostics, and how this test fits into clinical pathways for diagnosing and managing H. pylori infection.
Readers will find benchmarks and contextual policy discussion relevant to PLA molecular diagnostics, a summary of clinical context for sequencing-based antibiotic resistance testing, and practical information about where the service is typically performed. The content focuses on national implications for billing, coding specificity inherent to PLA codes, and factors payers consider when evaluating coverage for targeted molecular resistance assays.
Billing Code Overview
CPT code 0008U is a Proprietary Laboratory Analyses (PLA) code that describes the AmHPR Helicobacter pylori Antibiotic Resistance Panel produced by American Molecular Laboratories, Inc. The service is a gene sequence analysis performed to detect antibiotic resistance in Helicobacter pylori using a fresh tissue specimen or a fecal specimen.
Service Type: Laboratory — molecular diagnostic, sequencing-based antimicrobial resistance testing
Typical Site of Service: Clinical laboratory or reference laboratory processing specimens collected in outpatient clinics, inpatient facilities, or ambulatory settings
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 42-year-old patient presents with persistent dyspepsia and recent positive noninvasive testing for Helicobacter pylori infection. The treating gastroenterologist prescribes eradication therapy but wants to determine antibiotic susceptibility because the patient has had prior macrolide exposure and failed empirical therapy previously. During colonization assessment, the clinician obtains a fresh gastric biopsy specimen during upper endoscopy or collects a fresh fecal specimen for molecular testing. The specimen is sent to American Molecular Laboratories, Inc. for the AmHPR Helicobacter pylori Antibiotic Resistance Panel (0008U), a gene sequence analysis that identifies H. pylori antibiotic resistance markers to guide targeted therapy.
Typical clinical workflow:
-
The patient is evaluated in outpatient gastroenterology or primary care for symptoms suggestive of H. pylori infection.
-
Noninvasive testing (urea breath test, stool antigen) or endoscopic biopsy confirms infection or is clinically indicated; if resistance testing is needed, a fresh tissue or fecal specimen is collected.
-
Specimen handling follows laboratory instructions for preservation and transport to the performing laboratory.
-
The laboratory performs gene sequence analysis for known H. pylori resistance mutations and reports antibiotic resistance profile to the ordering clinician.
-
The clinician uses the report to select an appropriate antibiotic regimen and documents the test result and therapeutic decision in the medical record.
Typical site of service: outpatient gastroenterology clinic with endoscopy suite or outpatient specimen collection/clinical laboratory; specimens may originate from inpatient endoscopy when clinically indicated.
Service type: Proprietary Laboratory Analysis (PLA) — molecular diagnostic gene sequencing for pathogen antibiotic resistance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified modifier | Rarely used; reserved if payer requires a placeholder when no other modifier applies. |
11 | Judicially not a standard CMS modifier; in this input set used as default/placeholder | Use only if payer-specific guidance requires this code (rare). |
22 | Increased procedural services | When the laboratory documents substantially greater work than typical for the test (rare for PLA codes; use per payer rules). |
26 | Professional component | When billing is split and the physician/lab bills only the professional interpretation component (use with technical component TC if applicable). |
52 | Reduced services | If the test is completed but a portion of the usual service is not performed. |
53 | Discontinued procedure | If specimen collection or testing was discontinued for documented reasons prior to completion. |
62 | Two surgeons | Not typically applicable to this laboratory test; include only if two qualified providers share responsibility per payer policy. |
78 | Unplanned return to the operating/procedure room | Not applicable to the lab test itself; relevant if endoscopy requires reoperation. |
80 | Assistant surgeon | Not applicable to the laboratory analysis; relevant to procedural billing at time of biopsy. |
QK | Medical direction of two or more CRNAs | Not applicable to lab billing; included for comprehensive modifier awareness. |
QX | CRNA service with medical direction by physician | Not applicable to lab billing; see facility/endoscopy billing. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
208800000X | Gastroenterology | Gastroenterologists obtain gastric biopsies and order H. pylori resistance testing. |
207Q00000X | Pathology & Laboratory Medicine | Pathologists and laboratory directors oversee molecular testing and reporting. |
363A00000X | Clinical Laboratory | Clinical laboratory specialists and molecular diagnosticians perform sequencing and interpretation. |
208000000X | Family Medicine | Primary care physicians may order stool-based molecular H. pylori resistance testing and manage treatment. |
207L00000X | Infectious Disease | Infectious disease specialists interpret resistance profiles for complex or refractory cases. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
K29.70 | Gastritis, unspecified, without bleeding | Symptom complex prompting endoscopy and testing for H. pylori and potential resistance profiling. |
K29.50 | Gastritis, unspecified, with hemorrhage | When gastric inflammation with bleeding prompts biopsy and testing to guide eradication therapy. |
K25.9 | Gastric ulcer, unspecified | Peptic ulcer disease associated with H. pylori infection; resistance testing can guide eradication in ulcer management. |
K27.9 | Peptic ulcer, site unspecified, without hemorrhage or perforation | H. pylori is a common etiologic factor; resistance data support appropriate antibiotic selection. |
A04.6 | Infection due to Clostridium difficile | Included as a differential diagnosis for antibiotic-associated diarrhea; stool testing pathways may overlap when stool specimens are collected. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | Endoscopic procedure to obtain gastric biopsy specimens that may be submitted for 0008U testing. |
88305 | Level IV surgical pathology, gross and microscopic examination | Histologic evaluation of biopsy tissue; often performed on the same specimen before or alongside molecular testing. |
87480 | Infectious agent antigen detection by immunoassay, Helicobacter pylori; stool | Non-molecular stool antigen test used for initial diagnosis; may precede resistance testing. |
81299 | Unlisted molecular pathology procedure | Alternate coding if a payer does not recognize the PLA code; used per payer guidance (not preferred when 0008U applies). |
87045 | Culture, bacterial; other source, quantitative, with isolation and presumptive identification | Culture-based methods for H. pylori and antibiotic susceptibility testing; may be performed when available to corroborate molecular resistance findings. |